-
POSTER
The Use of TDF+ 3TC/ FTC Is Associated with an Improved Response to Pegylated
Interferon +
Ribavirin in HIV/HCV-co-infected Patients Receiving HAART: The Gesida 50/06 Study
J J Gonzalez-Garcia, J
Berenguer, E Condes, et al
PDF
Poster
Abstract
-
POSTER
No Evidence of
Drug-resistance Mutations in a Seroconverter Exposed to
Tenofovir Disoproxil
Fumarate Chemoprophylaxis in Africa
R
Atchison, L Peterson, T Leigler, et al
PDF Poster
Abstract-
Effect of
Tenofovir on Renal Function in Patients Using HAART
M
Horberg. B Tang, W Towne, et al
PDF Poster
Abstract
-
POSTER
Safety and
Efficacy of Tenofovir in Pregnant Women
A Haberl,
R Linde, A Reitter, et al
PDF Poster
Abstract
-
POSTER
The Cost of
Switching from Stavudine to Tenofovir in First-line ARV
Regimens in South Africa
I Sanne,
L Long, M Fox, S Rosen
PDF Poster
Abstract
-
Intracellular Accumulation of Tenofovir and Emtricitabine
in vitro Highlight the Inhibitor Role of
Efavirenz for Multridrug Resistance-Associated Protein 1,
MRP1
L
Bousquet, A Pruvost, N Didier, et al
Abstract
-
Compartmental Kinetics of Intracellular Tenofovir
C
Fletcher, T King, L Bushman, et al
Abstract
-
Low Tenofovir Concentrations in Cerebrospinal Fluid
B Best,
S Letendr, P Koopmans, et al
Abstract
-
POSTER
Intrapartum Tenofovir and Emtricitabine Reduces Development
of Low-level NNRTI Resistance
following Ingestion of Single-dose Nevirapine for Perinatal
HIV Prevention
B Chi, L
Frenkel, G Aldrovandi, et al
PDF Poster
Abstract-
POSTER
Comparison of Package-insert Recommendations for Renal
Dosing and Prescribed Dosing of
Products Containing Tenofovir: The VA Experience
B
Phillips, P
Belperio, L Mole, V Katseva
PDF Poster
Abstract-
POSTER
Tenofovir Use Is Associated with an Increase in Serum
Alkaline Phosphatase in the Swiss HIV
Cohort Study
C Fux, A
Rauch, M Simcock, et al
PDF Poster
Abstract-
Population Pharmacokinetics of Tenofovir in HIV-1-infected
Pregnant Women and Their Neonates:
TEmAA ANRS 12109
D Hirt,
S Yrien, E Rey, et al
Abstract
|
4th
International AIDS Society (IAS) Conference on
HIV
Pathogenesis, Treatment and Prevention |
Javanbakht M , Khanlou H, Chien C, et al
Abstract
Predictors of viral rebound in patients receiving a first line
tenofovir-containing combined
ARV therapy (cART) after attainment of suppressed viral load
Antinori A, Lorenzini P, Maggiolo F, et al
Abstract
Pre-exposure prophylaxis and timed intercourse for HIV-discordant couples
willing to conceive a
child
Vernazza P, Brenner I, Graf I, et al
Abstract
Trends and predictors of HIV-associated risk behaviors among injecting drug
users participating
in an HIV prevention trial, Bangkok
Vanichseni S, Martin M, Suntharasamai P, et al
Abstract
Efficacy and safety at 96 weeks of the new WHO first line regimen:
tenofovir-emtricitabine-
efavirenz in HIV-1 infected adults in Senegal
Landman R, Diallo M-B, Poupard M, et al
Abstract
Screening, enrollment, and follow-up of injecting drug users in an HIV
prevention trial in
Bangkok
Choopanya K, Martin M, Vanichseni S, et al
Abstract
Tubular amino acid reabsorption and urinary proteome analysis in HIV patients
treated with
antiretroviral therapy
Behrens G, Wittke S, Luecke T, et al
Abstract
Effect of tenofovir-selected RT K65R on response to subsequent
regimens
Shealey W , Shepherd B, Bress J, et al
Abstract
Increased Renal Impairment in Patients Receiving TDF+PI vs TDF+NNRTI
M Goicoechea, S
Liu, B Best, et al
Abstract
POSTER
Surveillance of Hepatitis
B Virus Mutations during Tenofovir Treatment in HIV/HBV-co-infected
Individuals
J Audsley, N
Arrafin, L Yuen, et al
PDF Poster
Abstract
POSTER
Antiretroviral Regimens
including Tenofovir or Stavudine + Lamivudine as NRTI Backbone Are
Associated with Higher Sustained Virological Response Rate to Pegylated
Interferon and
Ribavirin Treatment in HIV/HCV-co-infected Patients
JA Mira, R
Carrillo-Gómez, A Gutierrez-Valencia, et al
PDF Poster
Abstract
Tenofovir DF Salvage Therapy in HIV-infected Children and Further
Studies on Bone Mineral Density
J Purdy, R Gafni,
R Gafn, et al
Abstract
POSTER
Tenofovir Treatment Is
Associated with a Decrease in Calculated Glomerular Filtration Rates
in a
Large Observational Cohort
C Fux, M Simcock
M Wolbers, et al
PDF Poster
Abstract
Tenofovir Pharmacokinetics during Pregnancy, at Delivery and
Postpartum
S Burchett, B
Best, M Mirochnick, et al
Abstract
Tenofovir Resistance among HIV-infected Patients Failing a
Fixed-dose Combination of Stavudine
+
Lamivudine + Nevirapine in a Resource-limited Setting
S Sungkanuparph,
W Manosuthi, S Kiertiburanakul, et al
Abstract
Efficacy and Safety of Tenofovir-containing vs
non-Tenofovir-containing Regimens in Black ART-naive
Patients
J Gallant, A
Pozniak, S Staszewski, et al
Abstract
Risk Factors for Tenofovir-associated Nephrotoxicity Identified in
an HIV Clinic Cohort
H Wai, T
Katsivas, C Ballard, et al
Abstract
Transplacental Passage of Tenofovir and other Antiretrovirals at
Delivery
S Bonora, D
Gonzalez de Requena, E Chiesa, et al
Abstract
POSTER
Molecular Basis of
Antagonism between K70E and K65R Tenofovir-associated Mutations in
HIV-1 Reverse Transcriptase
R Kagan, T Lee,
S Potts, L Ross
PDF
Poster
Abstract
POSTER
Hepatitis B Virus Plasma Dynamics in HIV/HBV-co-infected Patients:
Significant Difference
in the Anti-viral Activity of Adefovir and Tenofovir
K Lacombe, PY
Boelle, J Gozlan, et al
PDF
Poster
Abstract
POSTER
Tenofovir and Renal
Dysfunction in Clinical Practice
R Moore, J
Keruly, J Gallant, et
al
PDF
Poster
Abstract
8th Int Congress on Drug Therapy in HIV
Infection
|
-
Tenofovir-associated nephrotoxicity in the first year of therapy
Rocha S., Xerinda S., Marques R., et al
Abstract
-
CD4
cells increase in patients receiving the combination of TDF/ddI-EC with or
without a NNRTI
JD Scott, M Mashburn, D Anderson
Abstract-
ARV-experienced patients receiving TDF + ddI in the RESIST studies had a
reduced CD4 response
B Clotet, E Negredo, PM Girard, et al
Abstract-
Tenofovir-associated nephrotoxicity in the first year of therapy
S Rocha, S Xerinda, R Marques, et al
Abstract-
Urinary proteome analysis by capillary electrophroesis coupled mass
spectrometry (CE-MS) for
detection of tenofovir-associated kidney damage in HIV patients
GMN Behrens, U Moebius, A Gurjanov, et al
Abstract-
Steady-state pharmacokinetics (PK) of tenofovir (TDF) and fosamprenavir (FPV)
after once daily
(QD) TDF with unboosted or ritonavir (r)-boosted twice daily (BID) FPV in
healthy volunteers
A Luber, D Slowinski, M Andrews, et al
Abstract-
Efficacy and safety of Tenofovir DF (TDF), Emtricitabine (FTC) and Efavirenz
(EFV) compared to
fixed dose Zidovudine/lamivudine (CBV) and EFV through 96 weeks in
antiretroviral treatment-naive
patients
A Pozniak, J Gallant, E DeJesus, et al
Abstract-
CD4+ T-cell evolution after tenofovir/didanosine backbone (TDF/DDI) in
presence of undetectable
HIV-RNA
C Torti, G Lapadula, P Barreiro, et al
Abstract-
Impact of switching virologically suppressed, HIV-infected patients from
fixed-dose zidovudine/
lamivudine (CBV) to fixed-dose tenofovir DF/emtricitabine (TVD)
E DeJesus, S Sharma, R Corales, et al
Abstract-
Switch from stavudine (d4T) to tenofovir DF (TDF) in combination with
lamivudine (3TC) and
efavirenz (EFV) resulted in continued virologic suppression and improvement in
lipoatrophy
through 2 years in HIV-infected patients
JVR Madruga, I Cassetti, J MAH Suleiman, et al
|
XVII
International AIDS Conference